Cargando…

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry

Immunosuppressed patients may be at high risk for breakthrough COVID-19 infection despite SARS-CoV-2 vaccination, due to an inadequate or negligible antibody response. Based on data from the Leukemia & Lymphoma Society (LLS) National Registry, 25% of patients with hematologic malignancies do not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenberger, Lee M, Saltzman, Larry A, Senefeld, Jonathon W, Johnson, Patrick W, DeGennaro, Louis J, Nichols, Gwen L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	905.Outcomes Research-Lymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701695/ http://dx.doi.org/10.1182/blood-2021-151419

Ejemplares similares

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic
por: Sweeney, Nathan W., et al.
Publicado: (2021)

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States
por: Neparidze, Natalia, et al.
Publicado: (2021)

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology
por: Hicks, Lisa K., et al.
Publicado: (2021)

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021)

COVID-19 in Children, Adolescents and Young Adults with Hematological Malignancies
por: Parker, Rebecca S, et al.
Publicado: (2021)

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
por: Choi, Yun, et al.
Publicado: (2021)

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021)

Association of Race, Ethnicity, Age and Socioeconomic Status with Access to Virtual Visits within the Brigham & Women's Hospital Division of Hematology during the COVID-19 Pandemic
por: Kwarteng-Siaw, Miriam, et al.
Publicado: (2021)

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis
por: Gong, Inna, et al.
Publicado: (2021)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
por: Smart, Dave, et al.
Publicado: (2021)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Blood Type Does Not Affect Morbidity or Mortality in COVID-19 Infections, As Assessed By a Clinical Severity Scoring System
por: Thomas, Katharine E, et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK
por: Cranmer, Holly, et al.
Publicado: (2020)

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients
por: Bussini, Linda, et al.
Publicado: (2022)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
por: Ip, Andrew, et al.
Publicado: (2020)

Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
por: Cook, Michael Roderick, et al.
Publicado: (2020)

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
por: D'Aiello, Angelica, et al.
Publicado: (2020)

IMMUNE THROMBOCYTOPENIA PURPURA ASSOCIATED WITH NOVEL CORONAVIRUS INFECTION
por: Camelo, R.M., et al.
Publicado: (2020)

Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
por: Reddy, Sneha T, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in CLL: how often is enough?
por: Mellinghoff, Sibylle C., et al.
Publicado: (2022)

A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
por: Dittus, Christopher, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

Therapeutic efficacy of the resorcylic acid lactone LL‐Z1640‐2 for adult T‐cell leukaemia/lymphoma
por: Oura, Masahiro, et al.
Publicado: (2023)

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

Use of glucarpidase (carboxypeptidase‐G2) in pediatric cancer patients: 11‐year experience of a tertiary center
por: Vila, Rocío, et al.
Publicado: (2023)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1lp3nhmqmpb71okn5kavallrat